It is the first LVAD trial to examine five-year outcomes and surpasses a previous Abbott study on HeartMate 3, which recorded a survival time of two years. The device was found to reduce morbidity and mortality, largely because of fewer deaths by stroke, clotting and bleeding.
The nonprofit Digital Medicine Society is partnering with the likes of Google and the FDA to develop a free resource designed to help digital health startups navigate the regulatory process.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Abbott wants to leap into the world of consumer wearables to track various health signals for better health for consumers and better growth of its business. Will it win hearts and minds?
A recent webinar hosted by MedCity News and sponsored by BioT shared insights on some of the ingredients to successful creation and execution of remote patient monitoring solutions supported by a cloud-based connected care platform with speakers from BioT and Abbott.
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
With the results of a recent trial, Abbott is seeking an expanded indication from the FDA for its CardioMEMS device, intended to prevent hospitalizations in patients with heart failure. It’s also hoping to win over national coverage from CMS.
Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.
Abbott announced the launch of the newly-approved NeuroSphere Virtual Clinic by which deep brain stimulation patients can have their devices programmed and reset remotely, from the comfort of their homes without having to travel to a specialist.
False negatives increase the risk that patients will not self-isolate or exercise other precautions — such as wearing a mask — and make more people sick than if they had had an accurate diagnosis.
NPR reported on the study by The Cleveland Clinic's Dr. Gary Procop, which has not been peer reviewed. Procop acknowledged that he had stored samples in a special solution not recommended by the company, which defended the ID NOW test.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing a crucial role. Diagnostics companies are racing to test in the most accurate way possible, biotech and pharma companies are moving mountains to quickly develop vaccines and study potential therapies, while digital health companies have stepped up to the plate […]
The diagnostics company said it had received the EUA for use of its ID NOW system, which can detect a positive result in as low as five minutes and a negative result in 13 minutes. ID NOW is mainly used in urgent care settings.
American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
A sooner-than-expected availability of a rival's continuous glucose monitoring system to Medicare patients sends Dexcom's stocks lower, but an analyst believes this will be temporary.